Emideltide (DSIP)
Emideltide / Delta Sleep-Inducing Peptide • Also called DSIP, Delta Sleep Inducing Peptide
DSIP is positioned as a sleep-regulation peptide, but there is no reliable pharmacy compounding pathway under the current posture.
Current status
Restricted
Sleep-related interest, with current federal compounding constraints still in play.
FDA category
Category 2
Can pharmacies compound this?
No
Reclassification expected?
Yes
Would need meaningful FDA guidance changes before clinics could treat it as a mainstream option.
Primary Use
Sleep-related interest
Also searched as
DSIP, Delta Sleep Inducing Peptide
Regulatory Timeline
Feb 27, 2026
Political pressure and market expectations increased around a future peptide reclassification review.
Sep 29, 2023
Current status signal recorded: Still treated as a restricted compounding ingredient..
Mar 15, 2023
FDA peptide compounding scrutiny intensified across 503A and 503B channels.
Get notified...
Get notified when Emideltide (DSIP) status changes
State-specific notes
Florida
Marketed online more often than dispensed compliantly.